TCM
ALGS icon

Triumph Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Triumph Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135
Closed -$1.26K – 1838
2025
Q4 		$1.26K Buy
+135
New +$1.27K ﹤0.01% 1541

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Triumph Capital Management's ALGS Position: Q1 2026 in Review

Triumph Capital Management sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 135 shares — an estimated $1.26K sold.

Triumph Capital Management first reported a position in ALGS in Q4 2025 and held it in 1 quarter. The position peaked at $1.26K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Triumph Capital Management reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Triumph Capital Management sold 135 Aligos Therapeutics shares in Q1 2026, an estimated $1.26K.
  • Triumph Capital Management first reported a position in Aligos Therapeutics in Q4 2025 and held it in 1 quarter.
  • Triumph Capital Management's Aligos Therapeutics position peaked at $1.26K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.